Because many patients with type 2 diabetes experience a decline in renal function over time and are at risk of progression to chronic kidney disease or end‐stage kidney disease,35 our observation that renal function was preserved in some subgroups of patients is clinically relevant, and suggests that SGLT2 inhibitors may delay progression to chronic kidney disease/end‐stage kidney disease. Here, SLC5A2 is linked to type 2 diabetes mellitus.